What's Happening?
Blank Bio, an applied AI research lab, has announced a $7.2 million seed financing round and a strategic collaboration with Pacific Biosciences (PacBio) to advance RNA foundation models for precision oncology. The collaboration aims to generate high-resolution
long-read RNA sequencing data from patient tumor samples to improve patient-level predictions in oncology. This initiative will utilize PacBio's HiFi long-read sequencing technology to capture detailed molecular data from tumor transcriptomes, which Blank Bio will use to train and evaluate its models. The funding will support the development of these models, expand collaborations with pharmaceutical and diagnostic companies, and create new datasets for applications in biomarkers, clinical trial design, and diagnostics.
Why It's Important?
This collaboration and funding are significant as they aim to enhance the precision of oncology treatments by leveraging advanced RNA sequencing technologies. By improving the ability to predict patient responses and disease progression, these models could lead to more personalized and effective cancer treatments. The partnership with PacBio allows Blank Bio to access cutting-edge sequencing technology, which is crucial for capturing the complex molecular details of tumors. This could potentially transform how clinical trials are designed and how patients are selected for specific therapies, ultimately improving outcomes and reducing costs in cancer care.
What's Next?
Blank Bio plans to use the seed financing to continue developing its RNA foundation models and expand its partnerships with pharmaceutical and diagnostic companies. The collaboration with PacBio will focus on generating and analyzing RNA sequencing data from a diverse range of cancer indications. This data will be used to refine the models and enhance their predictive capabilities. As the models are further developed, they may be integrated into clinical settings to support drug development and diagnostic processes, potentially leading to new standards in precision oncology.
